glp 1 chemical structure The GLP-1 weight loss revolution | Feature Human GLP-1 receptor transmembrane domain

The strongest published weight loss outcomes were reported at 48 weeks

Oral semaglutide is a tool, not a magic wand

Preliminary results indicate that such drugs might not only be effective for obesity and diabetes but also for a number of other diseases including osteoarthritis, Parkinson's disease and a range of conditions caused by a buildup of fat in the liver, known as nonalcoholic steatohepatitis (NASH) (Brandt, Mller, DiMarchi)

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) begin affecting appetite and blood sugar within days to weeks, but clinically meaningful outcomes develop more gradually

He added that the drugs effects on the brains emotion and reward pathways also suggest that they may be repurposed to treat other conditions besides obesity, such as substance use disorders

The Bottom Line Retatrutide causes diarrhea in 16-34% of users, depending on dose